Research map: SACF and GILA for in vitro transformation assessment of CRISPR/Cas9-edited cell therapy candidates: a multi-site study

Back to the article

Papers in this map

  1. Easy quantitative assessment of genome editing by sequence trace decomposition · Eva Karina Brinkman · 2014 · 2654 citations · Cited by this paper
  2. Applications of genome editing technologies in the treatment of human diseases · 2026 · Related
  3. Creation of human tumour cells with defined genetic elements · William C. Hahn · 1999 · 2361 citations · Cited by this paper
  4. Ultrasound-guided left heart injection: a safer and more efficient strategy for mouse thoracic aortic gene delivery · 2026 · Related
  5. Patient-derived tumour xenografts as models for oncology drug development · John J. Tentler · 2012 · 1317 citations · Cited by this paper
  6. Optimization and scale up strategies for reproducible AAV enrichment step on CIMmultus® QA HR line · 2026 · Related
  7. Rules for Making Human Tumor Cells · William C. Hahn · 2002 · 968 citations · Cited by this paper
  8. Antimicrobial resistance and gene therapy: emerging molecular strategies for a global health threat · 2026 · Related
  9. Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer · Sylvia Julien · 2012 · 372 citations · Cited by this paper
  10. AAV2 capsid clearance and neuronal trafficking dynamics in the central nervous system · 2026 · Related
  11. Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase · Tingting Sun · 2011 · 281 citations · Cited by this paper
  12. Precision rewriting of muscle genetics: therapeutic horizons of base and prime editing in skeletal muscle disorders · 2025 · Related
  13. An evaluation framework for new approach methodologies (NAMs) for human health safety assessment · Stanley T. Parish · 2020 · 209 citations · Cited by this paper
  14. rAAV8 encapsidated HMR-001/z enables high efficiency hepatic transduction and restores hemostasis in hemophilic mice · 2026 · Related
  15. The Ability to Form Primary Tumor Xenografts Is Predictive of Increased Risk of Disease Recurrence in Early-Stage Non–Small Cell Lung Cancer · Thomas John · 2010 · 183 citations · Cited by this paper
  16. In vitro and in vivo rescue of dopaminergic neurons in Parkinson’s disease models after Parkin gene therapy · 2026 · Related
  17. Transformation of Human and Murine Fibroblasts without Viral Oncoproteins · Jesse S. Boehm · 2005 · 177 citations · Cited by this paper
  18. Assessment of F/HN-pseudotyped lentiviral vector following intravenous delivery to mice · 2026 · Related
  19. Establishment and Characterization of a Panel of Human Uveal Melanoma Xenografts Derived from Primary and/or Metastatic Tumors · Fariba Némati · 2010 · 176 citations · Cited by this paper
  20. Drinkable gene therapy foam for the treatment of constrictive esophageal carcinoma · 2026 · Related
  21. Rapid Quantitative Evaluation of CRISPR Genome Editing by TIDE and TIDER · Eva Karina Brinkman · 2019 · 175 citations · Cited by this paper
  22. Tumorigenicity assessment of cell therapy products: The need for global consensus and points to consider · Yoji Sato · 2019 · 171 citations · Cited by this paper
  23. Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation · Asaf Rotem · 2015 · 142 citations · Cited by this paper
  24. Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia · Dinah V. Parums · 2024 · 94 citations · Cited by this paper
  25. Standardized cell sources and recommendations for good cell culture practices in genotoxicity testing · Elisabeth Lorge · 2016 · 92 citations · Cited by this paper
  26. Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma · Takahiro Kodama · 2016 · 83 citations · Cited by this paper
  27. Beyond the promise: evaluating and mitigating off-target effects in CRISPR gene editing for safer therapeutics · Rui Lopes · 2024 · 79 citations · Cited by this paper
  28. Design of a Tumorigenicity Test for Induced Pluripotent Stem Cell (iPSC)-Derived Cell Products · Shin Kawamata · 2015 · 74 citations · Cited by this paper
  29. Large DNA deletions occur during DNA repair at 20-fold lower frequency for base editors and prime editors than for Cas9 nucleases · Gue‐Ho Hwang · 2024 · 64 citations · Cited by this paper
  30. Ultra-sensitive detection of tumorigenic cellular impurities in human cell-processed therapeutic products by digital analysis of soft agar colony formation · Shinji Kusakawa · 2015 · 57 citations · Cited by this paper
  31. Predicting genotoxicity of viral vectors for stem cell gene therapy using gene expression-based machine learning · Adrian Schwarzer · 2021 · 51 citations · Cited by this paper
  32. Long-term observation reveals high-frequency engraftment of human acute myeloid leukemia in immunodeficient mice · Anna Paczulla · 2017 · 37 citations · Cited by this paper
  33. Tyrosine-Protein Phosphatase Nonreceptor Type 12 Is a Novel Prognostic Biomarker for Esophageal Squamous Cell Carcinoma · Xun Cao · 2012 · 33 citations · Cited by this paper
  34. Patient-derived bladder cancer xenografts: a systematic review · Carina Bernardo · 2015 · 31 citations · Cited by this paper
  35. Evaluation of two in vitro assays for tumorigenicity assessment of CRISPR-Cas9 genome-edited cells · Myriam Lemmens · 2021 · 19 citations · Cited by this paper
  36. Five Years of Progress in CRISPR Clinical Trials (2019–2024) · Kevin M. Davies · 2024 · 16 citations · Cited by this paper
  37. Non-clinical safety assessment of novel drug modalities: Genome safety perspectives on viral-, nuclease- and nucleotide-based gene therapies · Myriam Lemmens · 2024 · 13 citations · Cited by this paper
  38. Decreased expression of protein tyrosine phosphatase non-receptor type 12 is involved in the proliferation and recurrence of bladder transitional cell carcinoma · Yong-Rui Piao · 2015 · 8 citations · Cited by this paper
  39. In vitro NIH3T3 mouse embryonic fibroblast cell model does not predict AAV2 or AAVdj-mediated cell transformation · Luping Qiu · 2025 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)